舍曲林联合坦索罗辛治疗慢性前列腺炎顽固性尿道疼痛的近期疗效(1)
摘要：目的 探讨舍曲林联合坦索罗辛治疗慢性前列腺炎顽固性尿道疼痛的近期疗效。方法 收集2017年12月～2018年6月我院诊治的慢性前列腺炎顽固性尿道疼痛患者52例，采用随机数字表法分为观察组和对照组，每组26例。观察组给予舍曲林联合坦索罗辛治疗，对照组给予前列舒通联合坦索罗辛，比较两组治疗前与治疗8周后前列腺炎症状评分(CPSI)、抑郁自评量表评分(SDS)、国际勃起功能评分(IIEF-5)，疼痛缓解总有效率，血清炎症因子水平和不良反应发生率。结果 治疗后，两组CPSI、SDS评分较治疗前降低，IIEF-5评分较治疗前升高;且观察组CPSI、SDS评分低于对照组[(13.02±5.17)分vs(17.25±6.60)分]、[(40.78±11.92)分vs(48.25±15.09)分]，觀察组IIEF-5评分高于对照组[(19.39±5.72)分vs(14.45±4.81)分]，差异有统计学意义(P<0.05)。观察组疼痛缓解总有效率为80.77%，高于对照组的65.38%，差异有统计学意义(P<0.05);治疗后，两组IL-6、TNF-α水平较治疗前降低，且观察组IL-6、TNF-α水平低于对照组[(6.03±3.21)pg/ml vs(12.23±6.64)pg/ml]、[(13.72±7.96)pg/ml vs(18.21±9.81)pg/ml]，差异有统计学意义(P<0.05)。观察组不良反应总发生率高于对照组，但差异无统计学意义(P>0.05)。结论舍曲林联合坦索罗辛治疗慢性前列腺炎顽固性尿道疼痛患者疗效确切，可有效改善患者尿道疼痛，减轻炎症反应，提高生活质量，减轻抑郁情绪，且安全可靠。
关键词：慢性前列腺炎;尿道疼痛;舍曲林
中图分类号：R697+.33 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.24.026
文章编号：1006-1959(2019)24-0081-04
Short-term Efficacy of Sertraline Combined with Tamsulosin in the Treatment
of Refractory Urethral Pain in Chronic Prostatitis
FENG You-liang
(Department of Urology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China)
Abstract：Objective To investigate the short-term efficacy of sertraline combined with tamsulosin in the treatment of refractory urethral pain in chronic prostatitis. Methods 52 patients with refractory urethral pain of chronic prostatitis treated in our hospital from December 2017 to June 2018 were collected and divided into observation group and control group by random number table method， with 26 cases in each group. The observation group was given sertraline combined with tamsulosin， and the control group was given Qianlieshutong combined with tamsulosin.The prostate inflammation symptom score (CPSI)， self-depression scale (SDS)， and international erectile function score (IIEF-5) were compared between the two groups before and after 8 weeks of treatment reaction rate. Results After treatment， the CPSI and SDS scores of the two groups were lower than before treatment， and the IIEF-5 score was higher than before treatment. The CPSI and SDS scores of the observation group were lower than those of the control group [(13.02±5.17) points vs (17.25±6.60) points] ， [(40.78±11.92) points vs (48.25±15.09) points]， the IIEF-5 score of the observation group was higher than the control group [(19.39±5.72) points vs (14.45±4.81) points]，the difference was statistically significant (P<0.05). The total effective rate of pain relief in the observation group was 80.77%， which was higher than 65.38% in the control group，the difference was statistically significant (P<0.05). After treatment， the levels of IL-6 and TNF-α in the two groups were lower than before treatment. The levels of IL-6 and TNF-α in the group were lower than those in the control group [(6.03±3.21) pg/ml vs (12.23±6.64) pg / ml]， [(13.72±7.96) pg/ml vs (18.21±9.81) pg/ml]， the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was higher than that in the control group， but the difference was not statistically significant (P>0.05). Conclusion Sertraline combined with tamsulosin is effective in treating patients with refractory urethral pain of chronic prostatitis. It can effectively improve urethral pain， reduce inflammation， improve quality of life， reduce depression， and is safe and reliable., 百拇医药(冯友亮)
关键词：慢性前列腺炎;尿道疼痛;舍曲林
中图分类号：R697+.33 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.24.026
文章编号：1006-1959(2019)24-0081-04
Short-term Efficacy of Sertraline Combined with Tamsulosin in the Treatment
of Refractory Urethral Pain in Chronic Prostatitis
FENG You-liang
(Department of Urology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China)
Abstract：Objective To investigate the short-term efficacy of sertraline combined with tamsulosin in the treatment of refractory urethral pain in chronic prostatitis. Methods 52 patients with refractory urethral pain of chronic prostatitis treated in our hospital from December 2017 to June 2018 were collected and divided into observation group and control group by random number table method， with 26 cases in each group. The observation group was given sertraline combined with tamsulosin， and the control group was given Qianlieshutong combined with tamsulosin.The prostate inflammation symptom score (CPSI)， self-depression scale (SDS)， and international erectile function score (IIEF-5) were compared between the two groups before and after 8 weeks of treatment reaction rate. Results After treatment， the CPSI and SDS scores of the two groups were lower than before treatment， and the IIEF-5 score was higher than before treatment. The CPSI and SDS scores of the observation group were lower than those of the control group [(13.02±5.17) points vs (17.25±6.60) points] ， [(40.78±11.92) points vs (48.25±15.09) points]， the IIEF-5 score of the observation group was higher than the control group [(19.39±5.72) points vs (14.45±4.81) points]，the difference was statistically significant (P<0.05). The total effective rate of pain relief in the observation group was 80.77%， which was higher than 65.38% in the control group，the difference was statistically significant (P<0.05). After treatment， the levels of IL-6 and TNF-α in the two groups were lower than before treatment. The levels of IL-6 and TNF-α in the group were lower than those in the control group [(6.03±3.21) pg/ml vs (12.23±6.64) pg / ml]， [(13.72±7.96) pg/ml vs (18.21±9.81) pg/ml]， the difference was statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was higher than that in the control group， but the difference was not statistically significant (P>0.05). Conclusion Sertraline combined with tamsulosin is effective in treating patients with refractory urethral pain of chronic prostatitis. It can effectively improve urethral pain， reduce inflammation， improve quality of life， reduce depression， and is safe and reliable., 百拇医药(冯友亮)